Ulcerative Rectal Colitis: Tofacitinib Response Study

We are researching what factors may predict how well patients with ulcerative rectal colitis respond to Tofacitinib therapy. This could help improve treatment strategies for better patient care.

>2 years 6-10 visits Monitoring phase (IV)Post-Trial Drug Access No Placebo Standard Medicines OralGastroenterologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Xeljanz

Xeljanz is a medicine used to treat inflammatory immune conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tofacitinib

Tofacitinib is a substance that reduces immune system activity to treat inflammatory autoimmune conditions like rheumatoid arthritis and ulcerative colitis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Azienda Ospedaliero-Universitaria Di Cagliari

Gastroenterologia

Cagliari, Italy

Azienda Ospedaliera Policlinico Universitario Tor Vergata

Gastroenterologia

Ciampino, Italy

Sponsor: Universita' Degli Studi Di Roma Tor Vergata

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.